EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.

EAP 衍生的单克隆抗体用于豚鼠免疫细胞表型分析。

• 批准号: 10291475
• 负责人: MARK GEISBERG
• 金额: $ 60万
• 依托单位: SILVER LAKE RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10291475
• 关键词: Address; Affinity; Antibodies; Antibody Specificity; Antigen Targeting; Antigens; Binding; Bioinformatics; Biological Assay; Cavia; Cells; Disease; Ebola; Epitopes; Goals; Hybridomas; Immune; Immune Sera; Immunization; Influenza; Modeling; Monoclonal Antibodies; Mus; Peptides; Peripheral Blood Mononuclear Cell; Phenotype; Preparation; Production; Reagent; Research; Surface Antigens; Tissues; Tuberculosis; Validation; ZIKV infection; candidate validation; cytokine; new technology; novel; screening

The proposal addressed the need for novel monoclonal Abs (MAbs) to characterize subsets of immune cells and cytokines in the guinea pig model. The goal is to use their novel technology to produce high-affinity MAbs against six target antigens, focusing on surface markers of immune cells, and to characterize the specificity of antibodies with guinea pig PBMCs and tissue section. These new reagents will be available to significantly enhance research capabilities for tuberculosis and other diseases such as influenza, Ebola and Zika viral infections.

该建议解决了新型单抗(MAbs)在豚鼠模型中表征免疫细胞亚群和细胞因子的需要。他们的目标是利用他们的新技术来制备针对六种靶抗原的高亲和力单抗，重点放在免疫细胞的表面标记上，并用豚鼠PBMCs和组织切片来表征抗体的特异性。这些新试剂将可用于显著增强结核病和其他疾病(如流感、埃博拉和寨卡病毒感染)的研究能力。